BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discov 2020;25:1141-51. [PMID: 32660307 DOI: 10.1177/2472555220942123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Niranjan V, Setlur AS, Karunakaran C, Uttarkar A, Kumar KM, Skariyachan S. Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2. Struct Chem. [DOI: 10.1007/s11224-022-02020-z] [Reference Citation Analysis]
2 Mohan S, Dharani J, Natarajan R, Nagarajan A. Molecular docking and identification of G-protein-coupled receptor 120 (GPR120) agonists as SARS COVID-19 MPro inhibitors. J Genet Eng Biotechnol 2022;20:108. [PMID: 35849279 DOI: 10.1186/s43141-022-00375-8] [Reference Citation Analysis]
3 Azali MA, Mohamed S, Harun A, Hussain FA, Shamsuddin S, Johan MF. Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. J Genet Eng Biotechnol 2022;20:98. [PMID: 35792966 DOI: 10.1186/s43141-022-00368-7] [Reference Citation Analysis]
4 Farooq M, Khan AW, Ahmad B, Kim MS, Choi S. Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection. Front Pharmacol 2022;13:915565. [DOI: 10.3389/fphar.2022.915565] [Reference Citation Analysis]
5 Fischer M, Müller P, Scheidt HA, Luck M. Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers. Biochemistry 2022. [PMID: 35731976 DOI: 10.1021/acs.biochem.2c00042] [Reference Citation Analysis]
6 Munafò F, Donati E, Brindani N, Ottonello G, Armirotti A, De Vivo M. Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. Sci Rep 2022;12:10571. [PMID: 35732785 DOI: 10.1038/s41598-022-14664-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Aris P, Mohamadzadeh M, Wei Y, Xia X. In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID-19. IJMS 2022;23:6889. [DOI: 10.3390/ijms23136889] [Reference Citation Analysis]
8 Alam A, Agrawal GP, Khan S, Khalilullah H, Saifullah MK, Arshad MF. Towards the discovery of potential RdRp inhibitors for the treatment of COVID-19: structure guided virtual screening, computational ADME and molecular dynamics study. Struct Chem 2022;:1-15. [PMID: 35669792 DOI: 10.1007/s11224-022-01976-2] [Reference Citation Analysis]
9 Hamdy R, Mostafa A, Abo Shama NM, Soliman SSM, Fayed B. Comparative evaluation of flavonoids reveals the superiority and promising inhibition activity of silibinin against SARS-CoV-2. Phytother Res 2022. [PMID: 35596627 DOI: 10.1002/ptr.7486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mujwar S, Sun L, Fidan O. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19. J Food Biochem 2022;:e14219. [PMID: 35545850 DOI: 10.1111/jfbc.14219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105345] [Reference Citation Analysis]
12 Hung DT, Ghula S, Aziz JMA, Makram AM, Tawfik GM, Abozaid AA, Pancharatnam RA, Ibrahim AM, Shabouk MB, Turnage M, Nakhare S, Karmally Z, Kouz B, Le TN, Alhijazeen S, Phuong NQ, Ads AM, Abdelaal AH, Nam NH, Iiyama T, Kita K, Hirayama K, Huy NT. The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis 2022:S1201-9712(22)00237-5. [PMID: 35470021 DOI: 10.1016/j.ijid.2022.04.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Figueiredo DLA, Ximenez JPB, Seiva FRF, Panis C, Bezerra RDS, Ferrasa A, Cecchini AL, Medeiros AI, Almeida AMF, Ramão A, Boldt ABW, Moya CF, Chin CM, Paula D, Rech D, Gradia DF, Malheiros D, Venturini D, Tavares ER, Carraro E, Ribeiro EMSF, Pereira EM, Tuon FF, Follador FAC, Fernandes GSA, Volpato H, Cólus IMS, Oliveira JC, Rodrigues JHDS, Santos JLD, Visentainer JEL, Brandi JC, Serpeloni JM, Bonini JS, Oliveira KB, Fiorentin K, Lucio LC, Faccin-Galhardi LC, Ferreto LED, Lioni LMY, Consolaro MEL, Vicari MR, Arbex MA, Pileggi M, Watanabe MAE, Costa MAR, Giannini MJSM, Amarante MK, Khalil NM, Lima Neto QA, Herai RH, Guembarovski RL, Shinsato RN, Mainardes RM, Giuliatti S, Yamada-Ogatta SF, Gerber VKQ, Pavanelli WR, Silva WCD, Petzl-Erler ML, Valente V, Soares CP, Cavalli LR, Silva WA Jr. COVID-19: The question of genetic diversity and therapeutic intervention approaches. Genet Mol Biol 2021;44:e20200452. [PMID: 35421211 DOI: 10.1590/1678-4685-GMB-2020-0452] [Reference Citation Analysis]
14 Dilokthornsakul W, Kosiyaporn R, Wuttipongwaragon R, Dilokthornsakul P. Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies. J Integr Med 2022;20:114-25. [PMID: 35144898 DOI: 10.1016/j.joim.2022.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chavda VP, Patel AB, Vihol D, Vaghasiya DD, Ahmed KMSB, Trivedi KU, Dave DJ. Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update. Clinical Complementary Medicine and Pharmacology 2022;2:100021. [DOI: 10.1016/j.ccmp.2022.100021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett 2022;62:128629. [PMID: 35182772 DOI: 10.1016/j.bmcl.2022.128629] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 43.0] [Reference Citation Analysis]
17 Abookleesh FL, Al-Anzi BS, Ullah A. Potential Antiviral Action of Alkaloids. Molecules 2022;27:903. [PMID: 35164173 DOI: 10.3390/molecules27030903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Nguyen QV, Chong LC, Hor YY, Lew LC, Rather IA, Choi SB. Role of Probiotics in the Management of COVID-19: A Computational Perspective. Nutrients 2022;14:274. [PMID: 35057455 DOI: 10.3390/nu14020274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
19 Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, Kurbatskaia IN, Smirnov IV, Bulygin AA, Knorre VD, Fedorova OS, Varnek A, Osolodkin DI, Ishmukhametov AA, Egorov AM, Gabibov AG, Kuznetsov NA. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Front Pharmacol 2021;12:773198. [PMID: 34938188 DOI: 10.3389/fphar.2021.773198] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Khan S, Hussain A, Vahdani Y, Kooshki H, Mahmud Hussen B, Haghighat S, Fatih Rasul M, Jamal Hidayat H, Hasan A, Edis Z, Haj Bloukh S, Kasravi S, Mahdi Nejadi Babadaei M, Sharifi M, Bai Q, Liu J, Hu B, Akhtari K, Falahati M. Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: A probable prelude to control some variants of coronavirus including Delta. Arab J Chem 2021;14:103353. [PMID: 34909059 DOI: 10.1016/j.arabjc.2021.103353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Srinivasan K, Rao M. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. Ther Adv Infect Dis 2021;8:20499361211063016. [PMID: 34881025 DOI: 10.1177/20499361211063016] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Mule S, Singh A, Greish K, Sahebkar A, Kesharwani P, Shukla R. Drug repurposing strategies and key challenges for COVID-19 management. J Drug Target 2021;:1-17. [PMID: 34854327 DOI: 10.1080/1061186X.2021.2013852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Wu Y, Crich D, Pegan SD, Lou L, Hansen MC, Booth C, Desrochers E, Mullininx LN, Starling EB, Chang KY, Xie ZR. Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp). Molecules 2021;26:7438. [PMID: 34946521 DOI: 10.3390/molecules26247438] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
24 Naidu SAG, Mustafa G, Clemens RA, Naidu AS. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2. J Diet Suppl 2021;:1-30. [PMID: 34850656 DOI: 10.1080/19390211.2021.2006387] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Zhao J, Zhang G, Zhang Y, Yi D, Li Q, Ma L, Guo S, Li X, Guo F, Lin R, Luu G, Liu Z, Wang Y, Cen S. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors. Antiviral Res 2021;196:105209. [PMID: 34801588 DOI: 10.1016/j.antiviral.2021.105209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Piplani S, Singh PK, Winkler DA, Petrovsky N. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies. Mol Biomed 2021;2:28. [PMID: 34766004 DOI: 10.1186/s43556-021-00050-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Majdi H, Zar Kalai F, Yeddess W, Saidani M. Phenolic compounds as antiviral agents: An In-Silico investigation against essential proteins of SARS-CoV-2. NRFHH 2022;2:62-78. [DOI: 10.53365/nrfhh/143085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Arghiani N, Nissan T, Matin MM. Role of microRNAs in COVID-19 with implications for therapeutics. Biomed Pharmacother 2021;144:112247. [PMID: 34601190 DOI: 10.1016/j.biopha.2021.112247] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
29 Farmani AR, Mahdavinezhad F, Scagnolari C, Kouhestani M, Mohammadi S, Ai J, Shoormeij MH, Rezaei N. An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19. Drug Deliv Transl Res 2021. [PMID: 34542840 DOI: 10.1007/s13346-021-01067-5] [Reference Citation Analysis]
30 Srivastava M, Hall D, Omoru OB, Gill HM, Smith S, Janga SC. Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components. Microorganisms 2021;9:1794. [PMID: 34576690 DOI: 10.3390/microorganisms9091794] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Nemat A, Asady A. The Third Wave of the COVID-19 in Afghanistan: An Update on Challenges and Recommendations. J Multidiscip Healthc 2021;14:2043-5. [PMID: 34376985 DOI: 10.2147/JMDH.S325696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mslati H, Gentile F, Perez C, Cherkasov A. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. J Chem Inf Model 2021;61:3771-88. [PMID: 34313439 DOI: 10.1021/acs.jcim.1c00384] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
33 Anand U, Jakhmola S, Indari O, Jha HC, Chen ZS, Tripathi V, Pérez de la Lastra JM. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Front Immunol 2021;12:658519. [PMID: 34276652 DOI: 10.3389/fimmu.2021.658519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
34 Palko N, Grishina M, Potemkin V. Electron Density Analysis of SARS-CoV-2 RNA-Dependent RNA Polymerase Complexes. Molecules 2021;26:3960. [PMID: 34203564 DOI: 10.3390/molecules26133960] [Reference Citation Analysis]
35 Janik E, Niemcewicz M, Podogrocki M, Saluk-Bijak J, Bijak M. Existing Drugs Considered as Promising in COVID-19 Therapy. Int J Mol Sci 2021;22:5434. [PMID: 34063964 DOI: 10.3390/ijms22115434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
36 Madru C, Tekpinar AD, Rosario S, Czernecki D, Brûlé S, Sauguet L, Delarue M. Fast and efficient purification of SARS-CoV-2 RNA dependent RNA polymerase complex expressed in Escherichia coli. PLoS One 2021;16:e0250610. [PMID: 33914787 DOI: 10.1371/journal.pone.0250610] [Reference Citation Analysis]
37 Kifle ZD, Ayele AG, Enyew EF. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. J Environ Public Health 2021;2021:6631721. [PMID: 33953756 DOI: 10.1155/2021/6631721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
38 Li J, Liu S, Shi J, Wang X, Xue Y, Zhu HJ. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. ACS Pharmacol Transl Sci 2021;4:870-87. [PMID: 33855276 DOI: 10.1021/acsptsci.1c00016] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
39 Balkrishna A, Mittal R, Sharma G, Arya V. Computational insights of phytochemical-driven disruption of RNA-dependent RNA polymerase-mediated replication of coronavirus: a strategic treatment plan against coronavirus disease 2019. New Microbes New Infect 2021;41:100878. [PMID: 33815808 DOI: 10.1016/j.nmni.2021.100878] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Vandyck K, Abdelnabi R, Gupta K, Jochmans D, Jekle A, Deval J, Misner D, Bardiot D, Foo CS, Liu C, Ren S, Beigelman L, Blatt LM, Boland S, Vangeel L, Dejonghe S, Chaltin P, Marchand A, Serebryany V, Stoycheva A, Chanda S, Symons JA, Raboisson P, Neyts J. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. Biochem Biophys Res Commun 2021;555:134-9. [PMID: 33813272 DOI: 10.1016/j.bbrc.2021.03.096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
41 Hopkins C, Onweni C, Zambito V, Fairweather D, McCormick K, Ebihara H, Caulfield T, Zhang YS, Freeman WD. Platforms for Personalized Polytherapeutics Discovery in COVID-19. J Mol Biol 2021;433:166945. [PMID: 33753053 DOI: 10.1016/j.jmb.2021.166945] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Koulgi S, Jani V, V N MU, Sonavane U, Joshi R. Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2. J Biomol Struct Dyn 2021;:1-15. [PMID: 33682633 DOI: 10.1080/07391102.2021.1894985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Borbone N, Piccialli G, Roviello GN, Oliviero G. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. Molecules 2021;26:986. [PMID: 33668428 DOI: 10.3390/molecules26040986] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
44 Hall-Swan S, Antunes DA, Devaurs D, Rigo MM, Kavraki LE, Zanatta G. DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins. bioRxiv 2021:2021. [PMID: 33501448 DOI: 10.1101/2021.01.21.427315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Rehman MFU, Fariha C, Anwar A, Shahzad N, Ahmad M, Mukhtar S, Farhan Ul Haque M. Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Comput Struct Biotechnol J 2021;19:612-23. [PMID: 33398233 DOI: 10.1016/j.csbj.2020.12.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
46 Kumar R, Mishra S, Shreya, Maurya SK. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses. RSC Med Chem 2021;12:306-20. [PMID: 34046618 DOI: 10.1039/d0md00318b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tița O, Constantinescu MA, Tița MA, Georgescu C. Use of Yoghurt Enhanced with Volatile Plant Oils Encapsulated in Sodium Alginate to Increase the Human Body's Immunity in the Present Fight Against Stress. Int J Environ Res Public Health 2020;17:E7588. [PMID: 33086508 DOI: 10.3390/ijerph17207588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Jiang Y, Yin W, Xu HE. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem Biophys Res Commun 2021;538:47-53. [PMID: 32943188 DOI: 10.1016/j.bbrc.2020.08.116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]